» Articles » PMID: 35902807

Chromatin Structure in Cancer

Overview
Publisher Biomed Central
Specialty Cell Biology
Date 2022 Jul 28
PMID 35902807
Authors
Affiliations
Soon will be listed here.
Abstract

In the past decade, we have seen the emergence of sequence-based methods to understand chromosome organization. With the confluence of in situ approaches to capture information on looping, topological domains, and larger chromatin compartments, understanding chromatin-driven disease is becoming feasible. Excitingly, recent advances in single molecule imaging with capacity to reconstruct "bulk-cell" features of chromosome conformation have revealed cell-to-cell chromatin structural variation. The fundamental question motivating our analysis of the literature is, can altered chromatin structure drive tumorigenesis? As our community learns more about rare disease, including low mutational frequency cancers, understanding "chromatin-driven" pathology will illuminate the regulatory structures of the genome. We describe recent insights into altered genome architecture in human cancer, highlighting multiple pathways toward disruptions of chromatin structure, including structural variation, noncoding mutations, metabolism, and de novo mutations to architectural regulators themselves. Our analysis of the literature reveals that deregulation of genome structure is characteristic in distinct classes of chromatin-driven tumors. As we begin to integrate the findings from single cell imaging studies and chromatin structural sequencing, we will be able to understand the diversity of cells within a common diagnosis, and begin to define structure-function relationships of the misfolded genome.

Citing Articles

Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy.

Prabhakaran R, Thamarai R, Sivasamy S, Dhandayuthapani S, Batra J, Kamaraj C Epigenetics Chromatin. 2024; 17(1):31.

PMID: 39415281 PMC: 11484394. DOI: 10.1186/s13072-024-00554-6.


Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin.

Vlahopoulos S Int J Mol Sci. 2024; 25(16).

PMID: 39201306 PMC: 11354898. DOI: 10.3390/ijms25168621.


FASTKD1 as a diagnostic and prognostic biomarker for STAD: Insights into m6A modification and immune infiltration.

Yang Y, Gao Y, Liu X, Huang Z, Zhang Y, Zhang Y Exp Ther Med. 2024; 28(2):305.

PMID: 38873045 PMC: 11170332. DOI: 10.3892/etm.2024.12594.


CD-Loop: a chromatin loop detection method based on the diffusion model.

Shen J, Wang Y, Luo J Front Genet. 2024; 15:1393406.

PMID: 38770419 PMC: 11102972. DOI: 10.3389/fgene.2024.1393406.


3C methods in cancer research: recent advances and future prospects.

Yoon I, Kim U, Jung K, Song Y, Park T, Lee D Exp Mol Med. 2024; 56(4):788-798.

PMID: 38658701 PMC: 11059347. DOI: 10.1038/s12276-024-01236-9.


References
1.
Welch J, Ley T, Link D, Miller C, Larson D, Koboldt D . The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150(2):264-78. PMC: 3407563. DOI: 10.1016/j.cell.2012.06.023. View

2.
Corces-Zimmerman M, Hong W, Weissman I, Medeiros B, Majeti R . Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014; 111(7):2548-53. PMC: 3932921. DOI: 10.1073/pnas.1324297111. View

3.
Drews R, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith P . A pan-cancer compendium of chromosomal instability. Nature. 2022; 606(7916):976-983. PMC: 7613102. DOI: 10.1038/s41586-022-04789-9. View

4.
Sungalee S, Liu Y, Lambuta R, Katanayeva N, Donaldson Collier M, Tavernari D . Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci. Nat Genet. 2021; 53(5):650-662. DOI: 10.1038/s41588-021-00842-x. View

5.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View